Abstract
Endotoxin is a potent stimulator of the inflammatory response and is believed to initiate the pathology in Gram-negative sepsis. Agents are being developed that bind and neutralize or block the effects of endotoxin, with the goal of improving outcome in the treatment of sepsis. Strategies discussed in this article include anti-LPS antibodies, LPS binding proteins and lipoproteins, polymyxin B conjugates, lipid A analogues, and extracorporeal techniques for endotoxin removal.
MeSH terms
-
Acute-Phase Proteins*
-
Animals
-
Anti-Bacterial Agents / pharmacology
-
Antibodies, Bacterial / immunology
-
Antibodies, Bacterial / therapeutic use
-
Antimicrobial Cationic Peptides*
-
Arthropod Proteins
-
Blood Proteins / pharmacology
-
Carrier Proteins / pharmacology
-
Cathelicidins
-
Gram-Negative Bacterial Infections / therapy*
-
Humans
-
Invertebrate Hormones / pharmacology
-
Lipopolysaccharides / antagonists & inhibitors*
-
Lipopolysaccharides / immunology
-
Lipoproteins / pharmacology
-
Membrane Glycoproteins*
-
Membrane Proteins*
-
Polymyxin B / pharmacology
-
Renal Dialysis
-
Sepsis / therapy*
Substances
-
Acute-Phase Proteins
-
Anti-Bacterial Agents
-
Antibodies, Bacterial
-
Antimicrobial Cationic Peptides
-
Arthropod Proteins
-
Blood Proteins
-
Carrier Proteins
-
Cathelicidins
-
Invertebrate Hormones
-
Lipopolysaccharides
-
Lipoproteins
-
Membrane Glycoproteins
-
Membrane Proteins
-
antilipopolysaccharide factor (Limulus)
-
bactericidal permeability increasing protein
-
lipopolysaccharide-binding protein
-
Polymyxin B